Cargando…

Intratumor Heterogeneity of the Estrogen Receptor and the Long-term Risk of Fatal Breast Cancer

BACKGROUND: Breast cancer patients with estrogen receptor (ER)–positive disease have a continuous long-term risk for fatal breast cancer, but the biological factors influencing this risk are unknown. We aimed to determine whether high intratumor heterogeneity of ER predicts an increased long-term ri...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lindström, Linda S, Yau, Christina, Czene, Kamila, Thompson, Carlie K, Hoadley, Katherine A, van't Veer, Laura J, Balassanian, Ron, Bishop, John W, Carpenter, Philip M, Chen, Yunn-Yi, Datnow, Brian, Hasteh, Farnaz, Krings, Gregor, Lin, Fritz, Zhang, Yanhong, Nordenskjöld, Bo, Stål, Olle, Benz, Christopher C, Fornander, Tommy, Borowsky, Alexander D, Esserman, Laura J
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2018
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6037086/ https://www.ncbi.nlm.nih.gov/pubmed/29361175 http://dx.doi.org/10.1093/jnci/djx270

Ejemplares similares

Tamoxifen therapy benefit for patients with 70-gene signature high and low risk
por: van ‘t Veer, Laura J., et al.
Publicado: (2017)

Assessment of 25-Year Survival of Women With Estrogen Receptor–Positive/ERBB2-Negative Breast Cancer Treated With and Without Tamoxifen Therapy: A Secondary Analysis of Data From the Stockholm Tamoxifen Randomized Clinical Trial
por: Dar, Huma, et al.
Publicado: (2021)

Clinical and molecular characteristics of estrogen receptor‐positive ultralow risk breast cancer tumors identified by the 70‐gene signature
por: Johansson, Annelie, et al.
Publicado: (2022)

IP6K2 predicts favorable clinical outcome of primary breast cancer
por: Sandström, Josefine, et al.
Publicado: (2021)

C–X–C ligand 10 and C–X–C receptor 3 status can predict tamoxifen treatment response in breast cancer patients
por: Hilborn, Erik, et al.
Publicado: (2014)

Androgen receptor expression predicts beneficial tamoxifen response in oestrogen receptor-α-negative breast cancer
por: Hilborn, Erik, et al.
Publicado: (2016)

Progesterone receptor positivity is a predictor of long-term benefit from adjuvant tamoxifen treatment of estrogen receptor positive breast cancer
por: Nordenskjöld, Anna, et al.
Publicado: (2016)

PTPN2 deficiency along with activation of nuclear Akt predict endocrine resistance in breast cancer
por: Karlsson, Elin, et al.
Publicado: (2018)

Predictive relevance of HOXB13 protein expression for tamoxifen benefit in breast cancer
por: Jerevall, Piiha-Lotta, et al.
Publicado: (2010)

17β-Hydroxysteroid Dehydrogenase Type 14 Is a Predictive Marker for Tamoxifen Response in Oestrogen Receptor Positive Breast Cancer
por: Sivik, Tove, et al.
Publicado: (2012)

Low RAB6C expression is a predictor of tamoxifen benefit in estrogen receptor-positive/progesterone receptor-negative breast cancer
por: Fohlin, Helena, et al.
Publicado: (2020)

RAB6C is an independent prognostic factor of estrogen receptor-positive/progesterone receptor-negative breast cancer
por: Fohlin, Helena, et al.
Publicado: (2020)

Raptor localization predicts prognosis and tamoxifen response in estrogen receptor-positive breast cancer
por: Bostner, Josefine, et al.
Publicado: (2017)

The effects of PTPN2 loss on cell signalling and clinical outcome in relation to breast cancer subtype
por: Veenstra, Cynthia, et al.
Publicado: (2019)

Activation of Akt, mTOR, and the estrogen receptor as a signature to predict tamoxifen treatment benefit
por: Bostner, Josefine, et al.
Publicado: (2012)

Breast cancer survival and incidence of second primary cancers after 30 years in a randomized study of two versus five years of adjuvant tamoxifen therapy
por: Nordenskjöld, Anna, et al.
Publicado: (2023)

The mTOR effectors 4EBP1 and S6K2 are frequently coexpressed, and associated with a poor prognosis and endocrine resistance in breast cancer: a retrospective study including patients from the randomised Stockholm tamoxifen trials
por: Karlsson, Elin, et al.
Publicado: (2013)

MCM3 upregulation confers endocrine resistance in breast cancer and is a predictive marker of diminished tamoxifen benefit
por: Løkkegaard, Sanne, et al.
Publicado: (2021)

Mutational profiling of micro-dissected pre-malignant lesions from archived specimens
por: Nachmanson, Daniela, et al.
Publicado: (2020)

Oestrogen receptor co-activator AIB1 is a marker of tamoxifen benefit in postmenopausal breast cancer
por: Weiner, M., et al.
Publicado: (2013)

Risk stratification with Breast Cancer Index for late distant recurrence in patients with clinically low-risk (T1N0) estrogen receptor-positive breast cancer
por: Schroeder, Brock, et al.
Publicado: (2017)

Met and its ligand HGF are associated with clinical outcome in breast cancer
por: Veenstra, Cynthia, et al.
Publicado: (2016)

High expression of stromal PDGFRβ is associated with reduced benefit of tamoxifen in breast cancer
por: Paulsson, Janna, et al.
Publicado: (2016)

Time dependent effects of adjuvant tamoxifen therapy on cerebrovascular disease: results from a randomised trial
por: Rosell, J, et al.
Publicado: (2011)

Genetic variants of CYP3A5, CYP2D6, SULT1A1, UGT2B15 and tamoxifen response in postmenopausal patients with breast cancer
por: Wegman, Pia, et al.
Publicado: (2007)

Atypical Ductal Hyperplasia at the Margin of Lumpectomy Performed for Early Stage Breast Cancer: Is there Enough Evidence to Formulate Guidelines?
por: Baker, Jennifer L., et al.
Publicado: (2012)

Risk of hospitalisation and death due to bone fractures after breast cancer: a registry-based cohort study
por: Colzani, Edoardo, et al.
Publicado: (2016)

The breast pre-cancer atlas illustrates the molecular and micro-environmental diversity of ductal carcinoma in situ
por: Nachmanson, Daniela, et al.
Publicado: (2022)

Flow cytometric analysis of S-phase fraction in breast carcinomas using gating on cells containing cytokeratin. South East Sweden Breast Cancer Group.
por: Wingren, S., et al.
Publicado: (1994)

Genotype of metabolic enzymes and the benefit of tamoxifen in postmenopausal breast cancer patients
por: Wegman, Pia, et al.
Publicado: (2005)

Akt kinases in breast cancer and the results of adjuvant therapy
por: Stål, Olle, et al.
Publicado: (2003)

The Prognostic Implications of Macrophages Expressing Proliferating Cell Nuclear Antigen in Breast Cancer Depend on Immune Context
por: Campbell, Michael J., et al.
Publicado: (2013)

Significance of S-phase fraction and hormone receptor content in the management of young breast cancer patients.
por: Stål, O., et al.
Publicado: (1992)

Prognostic and Predictive Significance of Stromal Tumor-Infiltrating Lymphocytes (sTILs) in ER-Positive/HER2−Negative Postmenopausal Breast Cancer Patients
por: Pousette, Jenny, et al.
Publicado: (2022)

Is Genetic Background Important in Lung Cancer Survival?
por: Lindström, Linda S., et al.
Publicado: (2009)

Current Landscape of Breast Cancer Imaging and Potential Quantitative Imaging Markers of Response in ER-Positive Breast Cancers Treated with Neoadjuvant Therapy
por: Jones, Ella F., et al.
Publicado: (2020)

Prognostic utility of HOXB13 : IL17BR and molecular grade index in early-stage breast cancer patients from the Stockholm trial
por: Jerevall, P-L, et al.
Publicado: (2011)

Data-driven leadership
por: Datnow, Amanda, et al.
Publicado: (2014)

Intratumoral therapies and in-situ vaccination for melanoma
por: Huppert, Laura A., et al.
Publicado: (2022)

Tumour-infiltrating lymphocytes as a prognostic and tamoxifen predictive marker in premenopausal breast cancer: data from a randomised trial with long-term follow-up
por: Lundgren, Christine, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_k85sub6r0hass2b54ht7ej3oo3